Study Start-Up and Activation Services
Ergomed delivers agile, data-driven and fast study start-up. A well-defined study start-up and activation strategy can significantly shorten your overall clinical trial, giving you a competitive advantage and improved chances of success. At Ergomed, we begin study start-up and activation planning as early as the request for information (RFI) stage, developing a study start-up plan that will be enhanced throughout the bidding process so that it is ready when needed. Our global coverage and data-driven approach also ensure we can identify rapid start-up sites with the best patient population to deliver the ‘first patient in’ (FPI) milestone. Led by a dedicated study start-up manager, we mobilize and synchronize our feasibility, site management and regulatory affairs resources to achieve even the most aggressive timelines.
As part of our innovative approach, our study start-up and activation teams:
- Evaluate critical success factors and use our proprietary intelligence database to combine historical data, trends and the latest developments to tailor our study start-up plans.
- Invest heavily in a robust, data-driven feasibility assessment at the outset to ensure we identify the right countries and sites.
- Use our deep understanding of the many interrelated steps and dependencies that are critical to success.
- Proactively mitigate risks and implement solutions to respond to the dynamic environment.
- Take responsibility for expediting your study start-up and delivering reliable results, because predictability is the name of the game.
Want to know the possible timelines for your protocol? Use our startup timelines tool.